Deep Bio (medical imaging): Empowering clinicians with AI-powered solutions for cancer pathology diagnostics. Deep Bio develops AI software, primarily its DeepDx® suite, to assist medical professionals in cancer pathology diagnostics. The platform analyzes whole-slide images of tissue specimens to detect cancer, score its severity (e.g., Gleason scores for prostate cancer), and quantify specific biomarkers. Key capabilities: AI-based cancer pathology image analysis, Detection and segmentation of cancer areas, Gleason scoring for prostate cancer, Quantification of biomarkers (e.g., Ki-67, ER, PR, HER2, PD-L1, c-MET), Analysis of various tissue types (prostate, breast, stomach, lung, ovarian). Deep Bio is paid-only, with most plans including a trial period.
TL;DR - Deep Bio
AI-powered cancer pathology diagnostic support.
Improves accuracy and consistency in cancer detection and biomarker quantification.
Addresses pathologist shortages and diagnostic variability with automated analysis.
Pricing: Paid only
Best for: Enterprises & pros
4.3/5 across review platforms
Pros & Cons
Pros
Enhances diagnostic accuracy and consistency
Reduces pathologist workload and subjectivity
Provides precise quantification of areas of interest and biomarkers
Accelerates turnaround time for diagnoses
Backed by extensive research, publications, and patents
Cons
DeepDx® solutions are for Research Use Only (RUO) in the United States (not FDA cleared)
Specific pricing information is not publicly available
Requires integration into existing pathology workflows
Ratings aggregated from independent review platforms. Learn more
Key Features
AI-based cancer pathology image analysisDetection and segmentation of cancer areasGleason scoring for prostate cancerQuantification of biomarkers (e.g., Ki-67, ER, PR, HER2, PD-L1, c-MET)Analysis of various tissue types (prostate, breast, stomach, lung, ovarian)Whole-slide image (WSI) analysisDiagnostic result visualization technologyTissue slide indexing technology
Pricing
Paid
Deep Bio offers paid plans. Visit their website for current pricing details.
Deep Bio develops AI software, primarily its DeepDx® suite, to assist medical professionals in cancer pathology diagnostics. The platform analyzes whole-slide images of tissue specimens to detect cancer, score its severity (e.g., Gleason scores for prostate cancer), and quantify specific biomarkers. By integrating state-of-the-art deep learning technology, Deep Bio aims to improve the accuracy, consistency, and reproducibility of diagnoses, addressing challenges like pathologist shortages and diagnostic variability.
The DeepDx® solutions are designed for various cancer types, including prostate and breast cancer, and provide metrics that are difficult to measure manually. This allows clinicians to optimize treatment decisions and enhance patient care. The company also offers DeepCDx™, an AI-enabled drug discovery solution to guide biopharmaceutical companies in developing new drugs by leveraging data and AI for diagnostic solutions.
Deep Bio is a company that develops AI-powered software solutions for cancer pathology diagnostics. Their primary product, DeepDx®, assists medical professionals by analyzing whole-slide images of tissue specimens to detect cancer, score its severity, and quantify biomarkers, aiming to improve diagnostic accuracy and efficiency.
How much does Deep Bio cost?
Specific pricing information for Deep Bio's products is not publicly available on their website. Interested parties are advised to contact Deep Bio directly for more information.
Is Deep Bio free?
No, Deep Bio's products are not free. They are advanced AI software solutions for medical diagnostics and drug discovery, indicating a paid model.
Who is Deep Bio for?
Deep Bio is for medical professionals, particularly pathologists and oncologists, as well as biopharmaceutical companies. It aims to empower clinicians with tools for optimized treatment decisions and assist drug discovery efforts.